Piper Sandler Downgrades Synopsys as AI Chip Shift Creates Headwinds
Piper Sandler downgraded Synopsys to Neutral, citing AI-driven chip industry shifts, risks to its IP business, and a challenging outlook for 2026.
NOTRELOAD AI
Intel Stock Gets a Boost as Demand for Data Center Chips Surges
KeyBanc upgrades Intel to Overweight with a $60 target, citing strong data center demand, near sell-out of server CPUs, and possible price increases in 2026.
Goldman Sachs Upgrades Arcus Biosciences to Buy on Strong Cancer Drug Data
Goldman Sachs upgraded Arcus Biosciences to Buy, raising its price target to $28 on promising results for its lead cancer drug Casdatifan.
Solid Biosciences Wins FDA Orphan Drug Status for Friedreich's Ataxia Treatment
Solid Biosciences receives FDA Orphan Drug designation for SGT-212, a dual-route gene therapy treating Friedreich's ataxia, with first patient dosed in clinical trial.
Bakkt Acquires DTR: Analyst Sees Strong Growth Ahead
Bakkt agrees to acquire Distributed Technologies Research in $150M stock deal. Clear Street analyst rates it a Buy with $39 target as stablecoin business expands.
Supreme Court Denies Hertz Appeal: $320M Owed to Bondholders After COVID Bankruptcy
US Supreme Court rejects Hertz's challenge to $320M+ bondholder payment ruling from its 2020 COVID bankruptcy, requiring make-whole premiums and higher interest rates.